International Assets Investment Management LLC Invests $137,000 in Edwards Lifesciences Co. (NYSE:EW)

International Assets Investment Management LLC bought a new position in Edwards Lifesciences Co. (NYSE:EW) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 1,478 shares of the medical research company’s stock, valued at approximately $137,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. DSM Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $28,000. Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the 1st quarter valued at about $28,000. First Community Trust NA purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $29,000. Riverview Trust Co purchased a new position in Edwards Lifesciences during the 1st quarter valued at about $34,000. Finally, Pingora Partners LLC purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $38,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $69.96 on Tuesday. The company has a 50 day moving average price of $76.71 and a 200-day moving average price of $84.66. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm has a market capitalization of $42.14 billion, a PE ratio of 30.16, a P/E/G ratio of 2.92 and a beta of 1.11. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. The company had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.66 earnings per share. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.7 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total transaction of $437,700.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $4,108,777.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total transaction of $437,700.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,108,777.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,250 shares of company stock worth $1,321,988. 1.29% of the stock is owned by company insiders.

Analysts Set New Price Targets

EW has been the subject of a number of recent research reports. Barclays lowered their price target on shares of Edwards Lifesciences from $101.00 to $90.00 and set an “overweight” rating for the company in a research report on Friday, July 26th. Truist Financial cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $110.00 to $82.00 in a research report on Thursday, July 25th. Stifel Nicolaus lowered their price target on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, Oppenheimer reduced their price objective on shares of Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating for the company in a research note on Thursday, July 25th. Fourteen equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $82.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.